FDG-PET/CT vs CECT-CAP upfront imaging for Pyrexia of Unknown Origin diagnosis
Official title: Comparison of FDG-PET/CT and CECT-CAP as Upfront Imaging Modality for the Diagnosis of Pyrexia of Unknown Origin : A Prospective Observational Study
Run by Post Graduate Institute of Medical Education and Research, Chandigarh · NCT07816783 · Data updated 2026-11-12
This trial tests whether FDG-PET/CT is as good as or better than CECT-CAP as the initial imaging test to help diagnose adults with fever of unknown origin.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 132 (estimated) |
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh Academic / other |
| Locations | 1 site (Chandigarh, Chandigarh) |
| Status | Recruiting |
| Started | April 9, 2026 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT07816783 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with fever ≥38.3°C on ≥2 occasions and PUO duration criteria, who have undergone initial routine evaluations.
✕Probably not a fit
Patients with contraindications to iodinated contrast, prior relevant imaging, pregnancy, or immunosuppression may not derive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study compares two upfront imaging approaches for adults with Pyrexia of Unknown Origin (PUO). Participants are randomized to receive either FDG-PET/CT or contrast-enhanced CT CAP as the initial imaging modality, alongside standard care. The goal is to see which imaging strategy leads to quicker or more accurate diagnosis and guides management. The trial builds on existing PUO diagnostic pathways and uses routine pre-imaging evaluations as eligibility criteria. No results are provided here, but prior PUO research suggests imaging choices can influence diagnostic yield and resource use.
Why it matters
Potential benefit: If FDG-PET/CT proves superior, patients may receive faster and more accurate diagnoses, potentially reducing invasive testing and hospital stays.
How similar studies have gone: Prior imaging studies in PUO have shown varied diagnostic yields; this trial tests a direct head-to-head comparison of two imaging strategies in a structured randomized design.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * irrespective of gender. * Fever ≥38.3°C documented on ≥2 occasions AND duration ≥3 weeks or inpatient fever ≥1 week without diagnosis despite routine evaluation. * Routine investigations to be done before labelling PUO: Full history \& examination, CBC, ESR/CRP, LFTs, RFTs, blood and urine cultures, urinalysis, ANA, RF, chest X-ray, abdominal ultrasound Exclusion Criteria: * Pregnancy. * Known case of immunosuppression * Contraindication or allergy to iodinated IV contrast (for CECT-CAP arm) that cannot be corrected * Prior FDG PET/CT or CECT-CAP performed prior to randomization for the current febrile illness that would preclude randomization
Where it's running
-
Post Graduate Institute of Medical Education and Research, Chandigarh, India
Chandigarh, Chandigarh, India Recruiting
Study contacts
- Principal investigator: Deba Prasad Dhibar, MD — Post Graduate Institute of Medical Education and Research, Chandigarh, India
- Study coordinator: Deba Prasad Dhibar, MD
- Email: drdeba_prasad@yahoo.co.in
- Phone: +911722756670
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.